Drug development. Lupus drug company asks FDA for second chance.
Couzin
Jennifer
J
D000974:Antibodies, Antinuclear / Q000032:analysis / Q000097:blood / Q000276:immunology; D000915:Antibody Affinity; D017326:Clinical Trials, Phase III as Topic; D017327:Clinical Trials, Phase IV as Topic; D017277:Drug Approval; D004345:Drug Industry; D006801:Humans; D008180:Lupus Erythematosus, Systemic / Q000188:drug therapy*; D008181:Lupus Nephritis / Q000188:drug therapy*; D009841:Oligonucleotides / Q000009:adverse effects / Q000627:therapeutic use*; D014481:United States; D014486:United States Food and Drug Administration
D000974:Antibodies, Antinuclear; D009841:Oligonucleotides; C094104:abetimus